These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9679223)

  • 1. A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination.
    Veng-Pedersen P; Widness JA; Wang J; Schmidt RL
    J Pharmacokinet Biopharm; 1997 Oct; 25(5):569-93. PubMed ID: 9679223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction for non-ideal tracer pharmacokinetic disposition by disposition decomposition analysis (DDA).
    Veng-Pedersen P; Hong SS; Widness JA; Schmidt RL
    Pharm Res; 1998 Sep; 15(9):1469-73. PubMed ID: 9755902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans.
    Veng-Pedersen P; Widness JA; Pereira LM; Peters C; Schmidt RL; Lowe LS
    J Pharm Sci; 1995 Jun; 84(6):760-7. PubMed ID: 7562419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.
    El-Komy MH; Widness JA; Veng-Pedersen P
    Drug Metab Dispos; 2011 Apr; 39(4):603-9. PubMed ID: 21209249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.
    Veng-Pedersen P; Freise KJ; Schmidt RL; Widness JA
    J Pharm Pharmacol; 2008 Oct; 60(10):1321-34. PubMed ID: 18812025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans.
    Veng-Pedersen P; Widness JA; Pereira LM; Schmidt RL; Lowe LS
    Biopharm Drug Dispos; 1999 May; 20(4):217-23. PubMed ID: 10440797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
    Yan X; Ruixo JJP; Krzyzanski W
    AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep.
    Veng-Pedersen P; Chapel S; Al-Huniti NH; Schmidt RL; Sedars EM; Hohl RJ; Widness JA
    J Pharmacol Exp Ther; 2003 Aug; 306(2):532-7. PubMed ID: 12750427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state volume of distribution of two-compartment models with simultaneous linear and saturated elimination.
    Wu X; Nekka F; Li J
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):447-59. PubMed ID: 27405818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
    Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
    Exp Hematol; 2001 Apr; 29(4):425-31. PubMed ID: 11301182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing a small molecule erythropoietin mimetic.
    Guarnieri F
    Methods Mol Biol; 2015; 1289():185-210. PubMed ID: 25709041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.
    Dubois A; Gsteiger S; Balser S; Pigeolet E; Steimer JL; Pillai G; Mentré F
    Clin Pharmacol Ther; 2012 Feb; 91(2):234-42. PubMed ID: 22205196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.
    Freise KJ; Widness JA; Segar JL; Schmidt RL; Veng-Pedersen P
    Pharm Res; 2007 Sep; 24(9):1653-9. PubMed ID: 17457660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of new measures of nonlinearity to parameter estimation and simulations in individual pharmacokinetic analyses.
    Khinkis L; Crotzer M
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):43-52. PubMed ID: 30607795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of various estimation methods for the parameters of Michaelis-Menten equation based on
    Cho YS; Lim HS
    Transl Clin Pharmacol; 2018 Mar; 26(1):39-47. PubMed ID: 32055546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between steady-state and single-dose plasma drug concentrations for pharmacokinetic systems with nonlinear elimination.
    Cheng HY; Jusko WJ
    Biopharm Drug Dispos; 1989; 10(5):513-28. PubMed ID: 2804255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonlinear pharmacokinetics: clinical Implications.
    Ludden TM
    Clin Pharmacokinet; 1991 Jun; 20(6):429-46. PubMed ID: 2044328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics in nonlinear and partially compartmentalized systems.
    Radziuk J
    Fed Proc; 1980 May; 39(7):2450-5. PubMed ID: 7371876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
    Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
    Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.
    George K
    Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.